

**Ginger as an effective anti-emetic agent for use in chemotherapy: In silico analysis of the interactions of ginger actives with the serotonin (5-HT<sub>3</sub>) receptor**

Lohning, Anna Elizabeth; Marx, Wolfgang

Unpublished: 01/01/2017

*Document Version:*  
Peer reviewed version

[Link to publication in Bond University research repository.](#)

*Recommended citation (APA):*  
Lohning, A. E., & Marx, W. (2017). *Ginger as an effective anti-emetic agent for use in chemotherapy: In silico analysis of the interactions of ginger actives with the serotonin (5-HT<sub>3</sub>) receptor*. Abstract from 4th International Symposium 2017, Nagoya, Japan.

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.

# 4<sup>th</sup> Annual International Symposium 2017

## Bioresource Sciences for Sustainable Development of Japan & Thailand

with kind thanks to  
Prof. Hideaki Yamaguchi,  
Graduate School and Faculty of Agriculture  
Meijo University, Japan

Presentation by Dr Anna Lohning  
Faculty of Health Sciences & Medicine  
Bond University  
Gold Coast, Australia



# Ginger as an effective anti-emetic agent for use in chemotherapy

*In silico* analysis of the interactions of ginger actives with the serotonin (5-HT<sub>3</sub>) receptor

***Lohning, Anna E., Marx, Wolfgang***



# Overview

- Rationale
- Background
- Aims
- Methods
- Results
- Conclusions & Future Directions

Journal of Molecular Graphics and Modelling 70 (2016) 315–327



ELSEVIER

Contents lists available at [ScienceDirect](#)

Journal of Molecular Graphics and Modelling

journal homepage: [www.elsevier.com/locate/JMGM](http://www.elsevier.com/locate/JMGM)



*In silico* investigation into the interactions between murine 5-HT<sub>3</sub> receptor and the principle active compounds of ginger (*Zingiber officinale*)

Anna E. Lohning, Wolfgang Marx\*, Liz Isenring

Faculty of Health Sciences & Medicine, Bond University, Gold Coast, 4229, Australia



# Rationale



- Chemotherapy-induced nausea and vomiting (*CINV*) poses a major obstacle to patients (eg. treatment cessation). Variable responses to current treatments for *CINV* reduce their effectiveness in some patients providing impetus to develop more effective treatments (Hsieh, 2015).
- Clinical trials have shown preliminary support for the use of ginger in multiple types of nausea (motion, morning sickness, chemotherapy-induced) (Marx, 2013).
- A key finding from a double-blinded, randomized-controlled trial (Marx, 2017) in chemotherapy-naïve patients was that intervention participants reported significantly better *CINV*-related quality of life (QoL) & less fatigue than placebo participants (Marx et al 2017).

# Rationale (cont'd)



- In conjunction with this on-going clinical research, our team are interested in mechanistic aspects of how ginger functions as an anti-emetic.
- *In vitro* studies have shown the active compounds in ginger
  - a) Inhibit serotonin-mediated signalling (possibly in a non-competitive manner)<sup>1</sup>
  - b) Inhibit serotonin (5-HT<sub>3</sub>)-induced contractions in guinea pig ileum<sup>2</sup>
- Current anti-emetic treatment for **CINV** (eg granisetron) target 5-HT<sub>3</sub> receptors
- Understanding the details of how ginger actives bind and interact with this receptor will help guide rational drug design for more effective treatments.

<sup>1</sup> Walstab, J. et al Neurogastroenterol. Motil., 25 (2013) 439-447 (e302);




<sup>2</sup> Pertz, J. et al Planta Med. 77 (10) (2011) 973–978

<sup>2</sup> Abdel-Aziz, H. et al Planta Med. 71 (2005) 609–616.



# Introduction



- A primary pathway for emesis relating to *CINV* is stimulation of the vagal afferent nerves causing release of high levels of serotonin (5-HT<sub>3</sub>)
- Serotonin binds to receptors on afferent nerves sending a signal to the central nervous system, mediating a range of physiological functions.
- Current treatment for *CINV* involves use of anti-emetics (*setrons*) that competitively inhibit 5-HT<sub>3</sub> receptors thus decreasing 5-HT response.



ECCs = enterochromaffin cells

# Introduction (cont'd)

- The 5-HT<sub>3</sub> subtype of serotonin receptors are cationic, pentameric ion channels. Other examples of this receptor type include GABA, glycine, nACh receptors.
- 5 distinct subunits (5-HT<sub>3<sub>A→E</sub></sub>) leads to complexity of function. Other small molecules (Zn<sup>2+</sup>●) effect functional state of receptor.
- Functionally, the channel can be either open, closed or desensitized – serotonin binds with high affinity to the open channel.




X-ray crystal structure of the 5-HT<sub>3</sub> receptor (4pir.pdb) (Hassaine 2014) A (top); B (side)




# Introduction (cont'd)


- Gingerols are the primary bioactives within the non-volatile, pungent component of the ginger rhizomes (*Zingiber officinale*).



Gingerols (n=6,8,10)



Shogaols (n=6,8,10)



Dehydoshogaols (n=6,8,10)

- *In vitro* studies by Abdel Aziz in 2005 found that 6S, 6G, 8G and 10G inhibited 5-HT<sub>3</sub>-induced contractions of the isolated guinea-pig ileum.
- Since they were unable to displace <sup>3</sup>HGR65630 (a competitive inhibitor) a non-competitive mechanism was proposed (potential allosteric site) Similar findings were reported by Walstab in 2013.
- However the mechanism remains unclear<sup>1,2</sup>

<sup>1</sup> Ryan, J.L., et al Support. Care Cancer 2- (2012) 1479-1489.

<sup>2</sup> Marx, W. et al Curr. Opin. Support. Palliat. Care 9(2) (2015) 189-195.

# Aims




1. To use *in silico* techniques to determine whether a group of ginger actives could bind preferentially to the serotonin or an allosteric site of the mouse 5-HT<sub>3</sub> receptor.
2. To compare the theoretically-derived interaction energies with those obtained for serotonin and a range of 5-HT<sub>3</sub> agonists and antagonists.

# Method:

## Target preparation

- Homopentameric mouse 5-HT<sub>3</sub> receptor (4pir.pdb)
- Both serotonin & allosteric sites are located at interface of two subunits (**principle/complementary**) with key interacting residues from both subunits (A<sub>P</sub>A<sub>C</sub>) extracted
- 2 subunits extracted for analysis (ECM/TM/ICD) \*
- Energy minimized (Gast-Hückel charges & H added)



\* SYBYLx2.1.1 molecular modelling software

# Method

## Ligand database preparation

- Structures obtained either from Pubchem/PDB databases or prepared in ChemDraw.


| Ligand                              | Type   |
|-------------------------------------|--|
| Serotonin, (5-HT)                   | cognate ligand   |
| 6,8,10-G<br>6,8,10-S<br>6,8,10-DHSG | Gingerols<br>Shogaols<br>Dehydroshogaols                 |
| capsaicin, curcumin                 | Structural analogs of ginger actives                     |
| granisetron,<br>ondansetron, etc    | Positive Controls (5-HT site) (Setrons)<br>(competitive) |
| PU02, bicuculline, etc              | Positive Controls (allosteric<br>site) (non-competitive) |
| Acetylcholine, GABA                 | Negative Controls (Decoys)                               |

| * Energy minimization Protocol |                  |
|--------------------------------|------------------|
| Forcefield                     | Amber FF99       |
| Charges                        | Gasteiger-Huckel |
| Method                         | Steepest Descent |
| Convergence                    | 0.5 kcal/mol     |

# Method:

## Molecular Docking (Surflex-Dock 2.1)

- Protomol method: Serotonin site (multi-channel) Allosteric site (residue-based)
- Partial Protein Flexibility docking approach (ligand AND protein atoms around site of interest).
- Poses ranked according to Total Score ( $1/K_d$ ) representing a theoretical binding affinity.
- *C-score* validation. Compares 4 scoring functions each with different weightings for non-bonded interactions)



Protomol area in serotonin site (A) and allosteric site (B)




# Method (Cont'd)

## 2. GRID Analysis

- Interaction energies calculated at each grid point (kcal/mol) (Goodford, 1985).
- Grid box (dimensions (**topx,y,z**; **botx,y,z**)) generated around each site. (0.33 Å resolution)
- A set of small atomic/molecular probes was selected to mimic the chemical properties of key functional groups of the ligands.

## 3. Sequence Alignment

- ClustalOmega alignment between mouse and human 5-HT<sub>3</sub> receptor sequences was performed to identify the degree of homology and identify conservation of residues likely to be important in ligand binding.



GRID for serotonin site

|        | Serotonin Site | Allosteric site |
|--------|----------------|-----------------|
| Bottom | 144.82         | 138.06          |
| Top    | 181.15         | 184.06          |
| Y      | 157.57         | 166.93          |
| y      | 193.9          | 209.93          |
| Z      | 231.82         | 250.75          |
| z      | 277.82         | 293.75          |

# Results – Summary of Molecular Docking

Sorted by clogP (high → low)

Non-polar

| compound      | clogP | Total Score SERO | Total Score ALLO |
|---------------|-------|------------------|------------------|
| 10-S          | 5.9   | 9.34             | 8.29             |
| 8-DHSG        | 5.7   | 8.56             | 6.61             |
| 10-G          | 5.3   | 10.8             | 8.26             |
| 6-DHSG        | 4.6   | 6.97             | 6.28             |
| 6-S           | 3.7   | 8.31             | 6.52             |
| PU02          | 3.7   | 5.8              | 4.33             |
| capsaicin     | 3.6   | 8.54             | 9.23             |
| curcumin      | 3.2   | 8.77             | 7.02             |
| bicurculline  | 2.6   | 7.09             | 6.01             |
| 6-G           | 2.5   | 8.7              | 8.26             |
| VUF1066       | 2.4   | 5.13             | 5.8              |
| ondansetron   | 2.1   | 5.22             | 4.85             |
| granisetron   | 1.5   | 5.51             | 4.87             |
| varenicline   | 0.8   | 5.09             | 4.23             |
| picrotoxin    | 0.5   | 4.77             | 4.96             |
| serotonin     | 0.2   | 5.63             | 6.02             |
| ginkgolide    | -0.4  | 4.25             | 3.94             |
| GABA          | -3.2  | 4.9              | 4.76             |
| acetylcholine | -3.7  | 4.9              | 4.98             |

polar

Sorted by Total Score (sero) (high → low)

| compound      | clogP | Total Score SERO | Total Score ALLO |
|---------------|-------|------------------|------------------|
| 10-G          | 5.3   | 10.8             | 8.26             |
| 10-S          | 5.9   | 9.34             | 8.29             |
| curcumin      | 3.2   | 8.77             | 7.02             |
| 6-G           | 2.5   | 8.7              | 8.26             |
| 8-DHSG        | 5.7   | 8.56             | 6.61             |
| capsaicin     | 3.6   | 8.54             | 9.23             |
| 6-S           | 3.7   | 8.31             | 6.52             |
| bicurculline  | 2.6   | 7.09             | 6.01             |
| 6-DHSG        | 4.6   | 6.97             | 6.28             |
| PU02          | 3.7   | 5.8              | 4.33             |
| serotonin     | 0.2   | 5.63             | 6.02             |
| granisetron   | 1.5   | 5.51             | 4.87             |
| ondansetron   | 2.1   | 5.22             | 4.85             |
| VUF1066       | 2.4   | 5.13             | 5.8              |
| varenicline   | 0.8   | 5.09             | 4.23             |
| acetylcholine | -3.7  | 4.9              | 4.98             |
| GABA          | -3.2  | 4.9              | 4.76             |
| picrotoxin    | 0.5   | 4.77             | 4.96             |
| ginkgolide    | -0.4  | 4.25             | 3.94             |

Sorted by Total Score (allo) (high → low)

| compound      | clogP | Total Score SERO | Total Score ALLO |
|---------------|-------|------------------|------------------|
| capsaicin     | 3.6   | 8.54             | 9.23             |
| 10-S          | 5.9   | 9.34             | 8.29             |
| 10-G          | 5.3   | 10.8             | 8.26             |
| 6-G           | 2.5   | 8.7              | 8.26             |
| curcumin      | 3.2   | 8.77             | 7.02             |
| 8-DHSG        | 5.7   | 8.56             | 6.61             |
| 6-S           | 3.7   | 8.31             | 6.52             |
| 6-DHSG        | 4.6   | 6.97             | 6.28             |
| serotonin     | 0.2   | 5.63             | 6.02             |
| bicurculline  | 2.6   | 7.09             | 6.01             |
| VUF1066       | 2.4   | 5.13             | 5.8              |
| acetylcholine | -3.7  | 4.9              | 4.98             |
| picrotoxin    | 0.5   | 4.77             | 4.96             |
| granisetron   | 1.5   | 5.51             | 4.87             |
| ondansetron   | 2.1   | 5.22             | 4.85             |
| GABA          | -3.2  | 4.9              | 4.76             |
| PU02          | 3.7   | 5.8              | 4.33             |
| varenicline   | 0.8   | 5.09             | 4.23             |
| ginkgolide    | -0.4  | 4.25             | 3.94             |


- **Serotonin** scored mid field in both sites (polar)
- **Ginger compounds** scored high in both sites (as did **structural analogs** (all amongst most hydrophobic))
- **Competitive antagonists** scored mid field at both sites (very similar clogPs)
- **Polar non-competitive antagonists (NCAs)** scored lowest in serotonin site. The more lipophilic NCAs scored higher in serotonin site. (Nb. allosteric modulators are more potent in heteromeric receptors)
- **Decoys** (highly polar) scored poorly in both sites. (Most polar scored mid range in allosteric site)

Polarity was a key factor for binding in serotonin site more than the allosteric site

# Results – Molecular Docking


## Serotonin site

- Connolly surface (top) depicts lipophilicity of receptor surface around serotonin site.
- Our results verify the lipophilic nature of site (orange contours (GRID 1.5 kcal/mol, strong interactions with hydrophobic probe))
- **Serotonin** (total score 5.7) and **10G** (total score 10.81) docked into the serotonin binding site.
- 10G docked into a location distinct and more hydrophobic than that of serotonin.
- Position of key residues forming ‘aromatic box’ (Y207, W156 P subunit; Y127, W63 C subunit)



10-geringol

serotonin






# Results – Molecular Docking

## Serotonin site

- Our results showed a positive correlation between ligand lipophilicity (clogP) and ligand flexibility and size.
- A cluster analysis showed ligands scored high that were :-



**Fig. 13.** (A) Scatter plots of rotatable bonds vs Total score with colour axis, clogP (B) Scatter plots of Volume vs Total score with colour axis, clogP.

# Results – Molecular Docking

## Serotonin site

- Our results confirmed the importance of key residues thought to stabilise serotonin in this site, especially **R65**, **N101**, **T154**.
- Our results identified novel interactions with serotonin (D177, E173) and dolasetron (E209) and gingerols (K211, E209, L157)
- GRID successfully predicted position of aromatic ring of docked ginger actives.

Loop A (**N97**, **N101**)




Loop B (**T53**, **T54**, **W156**)

Loop C (**F199**, **Y207**)

Loop D (**W63**, **R65**, **Y68**)

Loop E (**Y124**)

Loop F (**D177**, **S178**, **V180**)



Granisetron (atom colours) **ondasetron**;  
**dolasetron**; **romasetron**; **palonosetron**



# Results – Molecular Docking

- Serotonin site – total scores ranged from 4.25-10.81 (-logK<sub>D</sub>)
  - 10G scored highest (ginger actives & structural analogs scored highly)
- Allosteric site – total scores ranged from 3.94-9.23 (-logK<sub>D</sub>)
  - Capsaicin (structural analog) scored highest followed by gingerol compounds in allosteric site
- Experimental IC<sub>50</sub> data (where available) included for comparison with docking scores for highest binding pose/ligand.

| Compound                                      | IC <sub>50</sub>          | Serotonin Site                    |        |                     |                                   | Allosteric Site                   |        |                     |                                   |
|---|---------------------------|-----------------------------------|--------|---------------------|-----------------------------------|-----------------------------------|--------|---------------------|-----------------------------------|
|   |                           | Total score (-logK <sub>D</sub> ) | Cscore | Hbonds <sup>b</sup> | Interacting Residues <sup>c</sup> | Total score (-logK <sub>D</sub> ) | Cscore | Hbonds <sup>b</sup> | Interacting Residues <sup>c</sup> |
| <b>Ginger Compounds</b>                       |                           |                                   |        |                     |                                   |                                   |        |                     |                                   |
| 6G  | 30 uM (rat) <sup>i</sup>  | 8.7                               | 1      | 3                   | E209 R65                          | 8.26                              | 1      | 4                   | E219 Q56 F222 E53                 |
| 8G  | uM range <sup>ii</sup>    | 10.25                             | 5      | 4                   | T154 E209 R65                     | 8.84                              | 5      | 3                   | E53 R219 F222                     |
| 10G   | uM range <sup>ii</sup>    | 10.81                             | 4      | 5                   | T154 E209 K211 T152               | 8.26                              | 1      | 5                   | T280 I139 E53 Q56                 |
| 6S  | 9,3 uM (rat) <sup>i</sup> | 8.31                              | 0      | 2                   | N101 W156                         | 6.52                              | 0      | 3                   | E53 F222 Q56                      |
| 8S  | uM range <sup>ii</sup>    | 9.06                              | 5      | 4                   | R65 S155 T154                     | 7.19                              | 2      | 2                   | K54 F222                          |
| 10S   | uM range <sup>ii</sup>    | 9.34                              | 2      | 2                   | T152 N101                         | 8.29                              | 5      | 1                   | F222                              |
| 6DHSG   | -                         | 6.97                              | 0      | 3                   | T152 N101 K211                    | 6.28                              | 0      | 3                   | E53 Q56 K54                       |
| 8DHSG   | -                         | 8.56                              | 0      | 3                   | L157 N101 Y207                    | 6.61                              | 0      | 1                   | E186                              |
| 10DHSG  | -                         | 9.07                              | 2      | 2                   | L157 N101                         | 6.85                              | 4      | 3                   | E53 Q56 K54                       |
| <b>Endogenous Ligand</b>                      |                           |                                   |        |                     |                                   |                                   |        |                     |                                   |
| serotonin                                     | 7.8 uM <sup>ai</sup>      | 5.63                              | 4      | 5                   | E173 S176 D42 D177                | 6.02                              | 0      | 4                   | Q184 E53 D138 L137                |
| <b>Structural Analogues of ginger actives</b> |                           |                                   |        |                     |                                   |                                   |        |                     |                                   |
| Capsaicin                                     | -                         | 8.54                              | 0      | 4                   | R65 N101                          | 9.23                              | 1      | 3                   | K54 R219 F222                     |
| Curcumin                                      | -                         | 8.77                              | 0      | 9                   | R65 T154 S155 D177 S179           | 7.02                              | 0      | 3                   | R219 E53 E186                     |

Residues in blue (previously suggested by Hassaine to be important for stabilising serotonin

# Results – Molecular Docking

- The setron family of anti-emetics ranked mid-field at both sites
- Non-competitive ligands scored poorly as did decoys. (Nb. Allosteric ligands are more potent towards heteromeric targets)
- Cscores were high for 10G indicating a consensus between scoring functions for their overall ranking.
- Cscores were similarly high for serotonin, some setrons & non-competitive ligands.


| Compound                       | IC <sub>50</sub>               | Serotonin Site                    |        |                     |                                   | Allosteric Site                   |        |                     |                                   |
|--------------------------------|--------------------------------|-----------------------------------|--------|---------------------|-----------------------------------|-----------------------------------|--------|---------------------|-----------------------------------|
|                                |                                | Total score (-logK <sub>d</sub> ) | Cscore | Hbonds <sup>b</sup> | Interacting Residues <sup>c</sup> | Total score (-logK <sub>d</sub> ) | Cscore | Hbonds <sup>b</sup> | Interacting Residues <sup>c</sup> |
| <b>Competitive Antagonists</b> |                                |                                   |        |                     |                                   |                                   |        |                     |                                   |
| Ondansetron                    | 4.9 nM (human)                 | 5.22                              | 5      | 1                   | T154                              | 4.85                              | 0      | 1                   | Q56                               |
| Granisetron                    | 1.4 nM (human)                 | 5.51                              | 5      | 1                   | E209                              | 4.87                              | 0      | 0                   | -                                 |
| Palonosetron                   | 31.6 nM (rat)                  | 5.74                              | 0      | 1                   | R65                               | 5.1                               | 0      | 0                   | -                                 |
| Dolasetron                     | 20.03 nM (NG108-15)            | 6.9                               | 0      | 3                   | R65 T154                          | 5.43                              | 1      | 0                   | -                                 |
| Ramosetron                     | 11-12 nM (human)               | 6.48                              | 4      | 1                   | T154                              | 5.65                              | 2      | 2                   | P274 Q56                          |
| VUF10166[41]                   | 40nM (AB subunit only)         | 5.13                              | 5      | 1                   | R65                               | 5.8                               | 4      | 0                   | -                                 |
| <b>Agonist (non-specific)</b>  |                                |                                   |        |                     |                                   |                                   |        |                     |                                   |
| Varenicline[43]                | 5.9 uM[42] (EC <sub>50</sub> ) | 5.09                              | 4      | 2                   | R65 N101                          | 4.23                              | 3      | 1                   | P274                              |
| <b>Non-Competitive Ligands</b> |                                |                                   |        |                     |                                   |                                   |        |                     |                                   |
| PU02                           | 1.3 uM (human)                 | 5.8                               | 5      | 3                   | D177 S179                         | 4.33                              | 2      | 1                   | D138                              |
| Bicuculline                    | 191 uM[44]                     | 7.09                              | 5      | 1                   | R65                               | 6.01                              | 1      | 3                   | -                                 |
| Picrotoxin                     | 440 uM[44]                     | 4.77                              | 5      | 4                   | E102 S150 S136 N148               | 4.96                              | 0      | 4                   | Y46 N183 S136                     |
| Ginkgolide                     | 727 uM[44]                     | 4.25                              | 2      | 7                   | K211 S150 E102 T152 N101          | 3.94                              | 3      | 3                   | T280 D138 I139                    |
| <b>Decoys</b>                  |                                |                                   |        |                     |                                   |                                   |        |                     |                                   |
| Acetylcholine                  | -                              | 4.9                               | 0      | 0                   |                                   | 4.95                              | 3      | 1                   | -                                 |
| GABA                           | -                              | 4.9                               | 4      | 3                   | W156 R65                          | 4.76                              | 1      | 3                   | -                                 |

# Results: Molecular Docking

## Allosteric site

Allosteric modulation permits fine-tuning of ion permeation via signal dampening.

The larger volume allows gingerols to adopt a more extended conformation facilitating favourable hydrophobic interactions with the transmembrane region.



★ Picrotoxin (NCA) is able to differentiate between A & B subunits<sup>1</sup>.

# Results: Molecular Docking


## Allosteric site

Top scoring ligand, **capsaicin**. Ginger actives also score well.

This site was found to be less hydrophobic compared to the serotonin site.

(A): GRID contours for a hydrophobic probe (-0.5 kcal/mol).

(B): water probe (-11 kcal/mol) coincides with polar groups




Connolly surface coloured by lipophilic character



# Results: Molecular Docking

## Allosteric site

- Ginger actives ranked highly.
  - **Gingerols > shogaols > DHSGs**
- Order correlates with the higher polarity of the site.
- Unlike serotonin site, polarity was not the key determinant contributing to score
  - Eg. PU02 (clogP similar to ginger actives) scored low)



Superimposition of 6G, 8G and 10G

### Key Finding:

Flexibility and hydrogen bonding capacity played a key role in binding interaction



# Results:


## Sequence alignment (ClustalOmega)

- subunits **A** and **B** of the mouse & human 5-HT<sub>3</sub> receptors
- Key residues highlighted for :-
  - principle subunit (**blue shaded box**)
  - complementary subunit (**grey shaded box**)
  - pore-facing residues of TM2 (**red star \***)
  - TM regions M1-M4 (**underlined**).
- Results show human & mouse 5-HT<sub>3A</sub> share ~85% sequence homology while 5-HT<sub>3B</sub> share ~73%. Human A & B subunits share only ~44%.

### Key Finding:

All residues required for stabilising ginger compounds in both sites were conserved between mouse & human

B human  
A mouse  
A human  
B mouse



FASTA colouring scheme (based on residue type)

# Limitations

- Species differences
- Functional State
- Subunit Composition
- Transmembrane/ECM interface - another potential binding site
- Inherent in Molecular Docking approaches are
  - Inaccuracies in the energy models used to score potential ligand/receptor complexes
  - The inability of current methods to account for conformational changes that occur during the binding process not only for the ligand, but also for the receptor (ie. how to cope with protein flexibility (1000's of degrees of freedom))
  - The above can be alleviated by using the more robust, Molecular Dynamics (full protein flexibility) – see later.

# Conclusions / Future Directions

## Key Findings

- Serotonin bound to a site distinct from other ligands in serotonin site.
- Ligand hydrophobicity directly correlated to higher scoring in serotonin site while ligand flexibility and hydrogen bonding capacity facilitated more potent interactions at the allosteric site.
- Our results were in agreement with a number of key residues involved in stabilising serotonin (R65, N101 & T154) at the orthogonal site. Novel residues (E102 & R219) could be exploited in drug design.
- At allosteric site, novel residues, R219, Q56, F222, Q53 and I139 were important in stabilising ginger actives.
- Ginger compounds scored highly in both sites.
  - Structural characteristics (flexibility, hydrophobicity, Hbond acceptors/donors) enable them to exploit complementary features in a binding pocket. Similar dual roles have been observed.

# Conclusions / Future Directions

## Analytical analysis

Quantification of ginger actives was conducted in a range of commercial ginger products to determine (Marx et al (2016))



Contents lists available at [ScienceDirect](#)

ELSEVIER

European Journal of Integrative Medicine

journal homepage: [www.elsevier.com/eujim](http://www.elsevier.com/eujim)

Research paper

Determination of the concentration of major active anti-emetic constituents within commercial ginger food products and dietary supplements

[Wolfgang Marx\\*](#), [Elisabeth A. Isenring](#), [Anna E. Lohning](#)

Faculty of Health Sciences and Medicine, Bond University, Queensland, Australia



## Future Work in Progress

Clinical A larger clinical trial has been accepted for funding (NHMRC, Feb 2017).



Mechanistic Validation of docking results is currently being carried out to confirm stability of ligands at each site using molecular dynamics simulations (GROMACS).



# Preliminary MD Data

10 ns Molecular Dynamics (MD) simulation of serotonin in 5-HT<sub>3</sub> receptor (ECD) in explicit solvent

Gromacs Energies



## Protocol

(Gromacs 5.04)

Forcefield – gromos54a7

EM, NVT NPT (Berendsen thermostat/barostat),

Neighbour coupling (Verlet)

E'statics (Reaction-field)

MD – 10ns; 2 fs timestep.

VMD Trajectory.

# Clinical Research Team / Collaborators / Funding Bodies



## Research Team

Professor Liz Isenring

Head of Program, Nutrition & Dietetics  
Research Group

Bond University, Gold Coast, Australia

Dr. Wolfgang Marx

School of Allied Health,  
LaTrobe University, Melbourne, Australia



Australian Government

National Health and Medical Research Council

**Alexandra McCarthy**, Princess Alexandra Hospital, QLD, Australia, Division of Cancer Services, Institute of Health and Biomedical Innovation, Brisbane, QLD, Australia; School of Nursing, University of Auckland, Auckland, NZ.

**Dan McKavanagh**, School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia; School of Nursing, University of Auckland, Auckland, NZ.

**Luis Vitetta**, Medlab Clinical Ltd, Sydney, NSW, Australia/University of Sydney, Sydney Medical School, Sydney, NSW, Australia.

**Avni Sali**, National Institute of Integrative Medicine, Melbourne, VIC, Australia

*Arigatō gazaimasu*  
*Sawadee ka*  
*Thank you!*

Questions

